SEARCH

SEARCH BY CITATION

References

  • Bastion, Y., Brice, P., Haioun, C., Sonet, A., Salles, G., Marolleau, J.P., Espinouse, D., Reyes, F., Gisselbrecht, C. & Coiffier, B. (1995) Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood, 86, 32573262.
  • Van Besien, K.W., De Lima, M., Giralt, S.A., Moore, Jr, D.F., Khouri, I.F., Rondon, G., Mehra, R., Andersson, B.S., Dyer, C., Cleary, K., Przepiorka, D., Gajewski, J.L. & Champlin, R.E. (1997) Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplantation, 19, 977982.
  • Van Besien, K., Loberiza, Jr, F.R., Bajorunaite, R., Armitage, J.O., Bashey, A., Burns, L.J., Freytes, C.O., Gibson, J., Horowitz, M.M., Inwards, D.J., Marks, D.I., Martino, R., Maziarz, R.T., Molina, A., Pavlovsky, S., Pecora, A.L., Schouten, H.C., Shea, T.C., Lazarus, H.M., Rizzo, J.D. & Vose, J.M. (2003) Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood, 102, 35213529.
  • Branson, K., Chopra, R., Kottaridis, P.D., McQuaker, G., Parker, A., Schey, S., Chakraverty, R.K., Craddock, C., Milligan, D.W., Pettengell, R., Marsh, J.C., Linch, D.C., Goldstone, A.H., Williams, C.D. & Mackinnon, S. (2002) Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. Journal of Clinical Oncology, 20, 40224031.
  • Chakrabarti, S., Avivi, I., Mackinnon, S., Ward, K., Kottaridis, P.D., Osman, H., Waldmann, H., Hale, G., Fegan, C.D., Yong, K., Goldstone, A.H., Linch, D.C. & Milligan, D.W. (2002a) Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality. British Journal of Haematology, 119, 11251132.
  • Chakrabarti, S., Mackinnon, S., Chopra, R., Kottaridis, P.D., Peggs, K., O’Gorman, P., Chakraverty, R., Marshall, T., Osman, H., Mahendra, P., Craddock, C., Waldmann, H., Hale, G., Fegan, C.D., Yong, K., Goldstone, A.H., Linch, D.C. & Milligan, D.W. (2002b) High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood, 99, 43574363.
  • Chakrabarti, S., Mautner, V., Osman, H., Collingham, K.E., Fegan, C.D., Klapper, P.E., Moss, P.A. & Milligan, D.W. (2002c) Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood, 100, 16191627.
  • Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 12441253.
  • Chopra, R., McMillan, A.K., Linch, D.C., Yuklea, S., Taghipour, G., Pearce, R., Patterson, K.G. & Goldstone, A.H. (1993) The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin’s disease. A single-center eight-year study of 155 patients. Blood, 81, 11371145.
  • Cull, G.M., Haynes, A.P., Byrne, J.L., Carter, G.I., Miflin, G., Rebello, P., Hale, G., Waldmann, H. & Russell, N.H. (2000) Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. British Journal of Haematology, 108, 754760.
  • Deconinck, E., Foussard, C., Milpied, N., Bertrand, P., Michenet, P., Cornillet-LeFebvre, P., Escoffre-Barbe, M., Maisonneuve, H., Delwail, V., Gressin, R., Legouffe, E., Vilque, J.P., Desablens, B., Jaubert, J., Ramee, J.F., Jenabian, A., Thyss, A., Le Pourhiet-Le Mevel, A., Travade, P., Delepine, R. & Colombat, P. (2005) High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood, 105, 38173823.
  • Faulkner, R.D., Craddock, C., Byrne, J.L., Mahendra, P., Haynes, A.P., Prentice, H.G., Potter, M., Pagliuca, A., Ho, A., Devereux, S., McQuaker, G., Mufti, G., Yin, J.L. & Russell, N.H. (2004) BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood, 103, 428434.
  • Freedman, A.S., Neuberg, D., Mauch, P., Soiffer, R.J., Anderson, K.C., Fisher, D.C., Schlossman, R., Alyea, E.P., Takvorian, T., Jallow, H., Kuhlman, C., Ritz, J., Nadler, L.M. & Gribben, J.G. (1999) Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood, 94, 33253333.
  • Gallagher, C.J., Gregory, W.M., Jones, A.E., Stansfeld, A.G., Richards, M.A., Dhaliwal, H.S., Malpas, J.S. & Lister, T.A. (1986) Follicular lymphoma: prognostic factors for response and survival. Journal of Clinical Oncology, 4, 14701480.
  • Ho, A.Y., Devereux, S., Mufti, G.J. & Pagliuca, A. (2003) Reduced-intensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions. Bone Marrow Transplantation, 31, 551557.
  • Horning, S.J. & Rosenberg, S.A. (1984) The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. The New England Journal of Medicine, 311, 14711475.
  • Howe, R., Micallef, I.N., Inwards, D.J., Ansell, S.M., Dewald, G.W., Dispenzieri, A., Gastineau, D.A., Gertz, M.A., Geyer, S.M., Hanson, C.A., Lacy, M.Q., Tefferi, A. & Litzow, M.R. (2003) Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma. Bone Marrow Transplantation, 32, 317324.
  • Hunault-Berger, M., Ifrah, N. & Solal-Celigny, P. (2002) Intensive therapies in follicular non-Hodgkin lymphomas. Blood, 100, 11411152.
  • Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman, J.W. (2001) Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissue. IARC Press, Lyon.
  • Johnson, P.W., Rohatiner, A.Z., Whelan, J.S., Price, C.G., Love, S., Lim, J., Matthews, J., Norton, A.J., Amess, J.A. & Lister, T.A. (1995) Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. Journal of Clinical Oncology, 13, 140147.
  • Jones, R.J., Ambinder, R.F., Piantadosi, S. & Santos, G.W. (1991) Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood, 77, 649653.
  • Khouri, I.F., Saliba, R.M., Giralt, S.A., Lee, M.S., Okoroji, G.J., Hagemeister, F.B., Korbling, M., Younes, A., Ippoliti, C., Gajewski, J.L., McLaughlin, P., Anderlini, P., Donato, M.L., Cabanillas, F.F. & Champlin, R.E. (2001) Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood, 98, 35953599.
  • Lenz, G., Dreyling, M., Schiegnitz, E., Forstpointner, R., Wandt, H., Freund, M., Hess, G., Truemper, L., Diehl, V., Kropff, M., Kneba, M., Schmitz, N., Metzner, B., Pfirrmann, M., Unterhalt, M. & Hiddemann, W. (2004) Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood, 104, 26672674.
  • Lundin, J., Osterborg, A., Brittinger, G., Crowther, D., Dombret, H., Engert, A., Epenetos, A., Gisselbrecht, C., Huhn, D., Jaeger, U., Thomas, J., Marcus, R., Nissen, N., Poynton, C., Rankin, E., Stahel, R., Uppenkamp, M., Willemze, R. & Mellstedt, H. (1998) CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin’s lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin’s Lymphoma. Journal of Clinical Oncology, 16, 32573263.
  • Mandigers, C.M., Meijerink, J.P., Raemaekers, J.M., Schattenberg, A.V. & Mensink, E.J. (1998) Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18). Lancet, 352, 15221523.
  • Mandigers, C.M., Verdonck, L.F., Meijerink, J.P., Dekker, A.W., Schattenberg, A.V. & Raemaekers, J.M. (2003) Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplantation, 32, 11591163.
  • Martino, R., Caballero, M.D., Canals, C., Simon, J.A., Solano, C., Urbano-Ispizua, A., Bargay, J., Rayon, C., Leon, A., Sarra, J., Odriozola, J., Conde, J.G., Sierra, J. & San Miguel, J. (2001) Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. British Journal of Haematology, 115, 653659.
  • Micallef, I.N., Lillington, D.M., Apostolidis, J., Amess, J.A., Neat, M., Matthews, J., Clark, T., Foran, J.M., Salam, A., Lister, T.A. & Rohatiner, A.Z. (2000) Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. Journal of Clinical Oncology, 18, 947955.
  • Mijovic, A., Parker, J., Salisbury, J., Pagliuca, A. & Mufti, G.J. (1998) Autologous blood or bone marrow transplantation for relapsed and partially responding low-grade non-hodgkin’s lymphoma. Cancer Research Therapy and Control, 5, 253260.
  • Mills, W., Chopra, R., McMillan, A., Pearce, R., Linch, D.C. & Goldstone, A.H. (1995) BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 13, 588595.
  • Morris, E., Thomson, K., Craddock, C., Mahendra, P., Milligan, D., Cook, G., Smith, G.M., Parker, A., Schey, S., Chopra, R., Hatton, C., Tighe, J., Hunter, A., Peggs, K., Linch, D., Goldstone, A. & Mackinnon, S. (2004) Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood, 104, 38653871.
  • National Cancer Institute (1999) Cancer Therapy Evaluation Programme, Common Toxicity Criteria Manual, Common Toxicity Criteria, Version 2.0. Available at: http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf
  • Parimon, T., Au, D.H., Martin, P.J. & Chien, J.W. (2006) A risk score for mortality after allogeneic hematopoietic cell transplantation. Annals of Internal Medicine, 144, 407414.
  • Perez-Simon, J.A., Kottaridis, P.D., Martino, R., Craddock, C., Caballero, D., Chopra, R., Garcia-Conde, J., Milligan, D.W., Schey, S., Urbano-Ispizua, A., Parker, A., Leon, A., Yong, K., Sureda, A., Hunter, A., Sierra, J., Goldstone, A.H., Linch, D.C., San Miguel, J.F. & Mackinnon, S. (2002) Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood, 100, 31213127.
  • Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H.G., Beatty, P., Hows, J. & Thomas, E.D. (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplantation, 15, 825828.
  • Ratanatharathorn, V., Uberti, J., Karanes, C., Abella, E., Lum, L.G., Momin, F., Cummings, G. & Sensenbrenner, L.L. (1994) Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin’s lymphoma. Blood, 84, 10501055.
  • Rodig, S.J., Abramson, J.S., Pinkus, G.S., Treon, S.P., Dorfman, D.M., Dong, H.Y., Shipp, M.A. & Kutok, J.L. (2006) Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clinical Cancer Research, 12, 71747179.
  • Salisbury, J.R., Rapson, N.T., Codd, J.D., Rogers, M.V. & Nethersell, A.B. (1994) Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin’s lymphomas. Journal of Clinical Pathology, 47, 313317.
  • Schouten, H.C., Qian, W., Kvaloy, S., Porcellini, A., Hagberg, H., Johnson, H.E., Doorduijn, J.K., Sydes, M.R. & Kvalheim, G. (2003) High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. Journal of Clinical Oncology, 21, 39183927.
  • Sorror, M.L., Maris, M.B., Storb, R., Baron, F., Sandmaier, B.M., Maloney, D.G. & Storer, B. (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood, 106, 29122919.
  • Valcarcel, D., Martino, R., Sureda, A., Canals, C., Altes, A., Briones, J., Sanz, M.A., Parody, R., Constans, M., Villela, S.L., Brunet, S. & Sierra, J. (2005) Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. European Journal of Haematology, 74, 144151.
  • Verdonck, L.F., Dekker, A.W., Lokhorst, H.M., Petersen, E.J. & Nieuwenhuis, H.K. (1997) Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin’s lymphoma. Blood, 90, 42014205.
  • Vigouroux, S., Michallet, M., Porcher, R., Attal, M., Ades, L., Bernard, M., Blaise, D., Tabrizi, R., Garban, F., Cassuto, J.P., Chevalier, P., Facon, T., Ifrah, N., Renaud, M., Tilly, H., Vernant, J.P., Kuentz, M., Bourhis, J.H., Bordigoni, P., Deconinck, E., Lioure, B., Socie, G. & Milpied, N. (2007) Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica, 92, 627634.